ArticleJNCI cancer spectrum2019

Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes.

Hajime Uno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.